GAVI vaccine alliance says 75 countries keen to join 'COVAX' — COVID-19 vaccine access facility

The 75 countries, which would finance the vaccines from public budgets, will partner with up to 90 poorer countries to provide them with access.

Reuters July 17, 2020 12:12:45 IST
GAVI vaccine alliance says 75 countries keen to join 'COVAX' — COVID-19 vaccine access facility

More than 75 countries have expressed interest in joining the COVAX financing scheme designed to guarantee fast and equitable access globally to COVID-19 vaccines, the GAVI vaccines alliance said on Wednesday.

The 75 countries, which would finance the vaccines from public budgets, will partner with up to 90 poorer countries supported through voluntary donations to GAVI's COVAX Advance Market Commitment (AMC), the alliance said in a statement.

"COVAX is the only truly global solution to the COVID-19 pandemic," Seth Berkley, GAVI's chief executive, said in a statement.

"For the vast majority of countries, whether they can afford to pay for their own doses or require assistance, it means receiving a guaranteed share of doses and avoiding being pushed to the back of the queue, as we saw during the H1N1 pandemic a decade ago."

Together, this group of up to 165 countries represents more than 60% of the world's population and the interest is a vote of confidence in efforts to secure global access to COVID-19 vaccines, GAVI's statement added.

COVAX is co-led by GAVI, the World Health Organization and the CEPI Coalition for Epidemic Preparedness Innovations. Its aim is to deliver 2 billion doses of effective, approved COVID-19 vaccines by the end of 2021.

The shots will be delivered equally to participating countries proportional to their populations, GAVI said, and deployed initially for healthcare workers.

GAVI said last month it had raised $567 million from international donors towards an initial goal of $2 billion to buy vaccines via the COVAX Advanced Market Commitment.

More than 100 potential COVID-19 vaccines are in development, with at least 20 in human clinical trials, as scientists seek ways to protect people against infection with the pandemic disease.

AstraZeneca, which is developing a potential COVID-19 shot known as AZD1222, has agreed to supply 300 million doses to COVAX if the vaccine proves effective and is licensed.

Berkley said that even for countries already pursuing bilateral deals with drugmakers, the COVAX scheme could help reduce their risk if one or more vaccine candidates fail.

 

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Moderna, Pfizer publish COVID-19 vaccine trial blueprints amid criticism of Donald Trump's response to pandemic
World

Moderna, Pfizer publish COVID-19 vaccine trial blueprints amid criticism of Donald Trump's response to pandemic

The disclosures are aimed at addressing growing suspicion that Trump’s drive to produce COVID-19 vaccine before the presidential election could result in a product that was unsafe

Under fire for vaccine safety, AstraZeneca releases 111-page human trial blueprint
World

Under fire for vaccine safety, AstraZeneca releases 111-page human trial blueprint

The company has released few details about the two cases of serious illness in its trial.

Immune response of children to COVID-19 different from adults leading to less severe symptoms and complications
Health

Immune response of children to COVID-19 different from adults leading to less severe symptoms and complications

The difference in IL-17A levels in children and adults was more prominent after excluding the MIS-C group who were hospitalised in a later stage of the disease.